Navigation Links
Valeant Pharmaceuticals Announces Resignation of Michael Van Every From Valeant's Board of Directors
Date:8/18/2011

MISSISSAUGA, Ontario, Aug. 18, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that Michael Van Every has resigned from Valeant's Board of Directors due to health reasons.

"We want to thank Michael for his many years of service to the Company, first at Biovail and then, following the merger of Biovail and Valeant, as part of the new Valeant Board," stated J. Michael Pearson, chairman and chief executive officer.  "Michael's accounting expertise was a tremendous asset to Company and brought a much needed stability to the financial organization during his tenure as Head of the Finance and Audit Committee.  Michael's counsel will be missed and we wish him well in his recovery."

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

(Logo:  http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Valeant Pharmaceuticals Reports 2011 Second Quarter Financial Results
2. Valeant Pharmaceuticals Announces Approval of Sublinox® in Canada
3. Valeant Pharmaceuticals Announces Distribution Agreement for Zuacta™ in Canada
4. Valeant Pharmaceuticals Agrees to Acquire Ortho Dermatologics
5. Sanofi Divests Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc.
6. Valeant Pharmaceuticals Agrees to Acquire Dermik
7. Valeant Pharmaceuticals Announces License Agreement With Meda for North American Rights for Elidel® and Xerese™
8. Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results
9. Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction
10. Valeant Pharmaceuticals to Announce 2011 First Quarter Results on May 9, 2011
11. Valeant Pharmaceuticals Responds to Cephalon Boards Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
(Date:6/23/2016)... Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment ... Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... General Manager of Astellas Farma Colombia ... ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Surgical Procedure Volumes: Global Analysis (United States, China, Japan, ... report to their offering. ... tool for healthcare business planners, provides surgical procedure volume ... surgery trends with an in-depth analysis of growth drivers ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Finally, a ... after venous procedures, dermaka cream can be incorporated into the post-surgical treatment plans of ... surgical procedures. , dermaka cream is very effective for bruising and causes a ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Dr. Seema Daulat, ... Evans Dermatology in the South Lamar location as of July 13, 2016. , Dr. ... School. As a medical student, she regularly volunteered at the Agape Clinic serving Dallas’ ...
Breaking Medicine News(10 mins):